Comparison
Mazdutide vs. Semaglutid
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Metabolic
Metabolic
CAS no.
2259884-03-0
910463-68-2
Molecular weight
4790 g/mol
4113.6 g/mol
Half-life
132 h
165 h
Sequence
synthetisches Oxyntomodulin-Analogon (39 Aminosäuren) mit Fettsäureseitenkettemodifiziertes GLP-1-Analogon (31 AS) mit C18-Fettsäure-LinkerMechanism of action
Mazdutide
Mazdutide is a dual agonist at the GLP-1 and glucagon receptors and is structurally derived from the gut hormone oxyntomodulin. The GLP-1 component mediates glucose-dependent insulin secretion, inhibition of glucagon secretion at elevated blood glucose, and modulation of appetite and gastric emptying. The glucagon component can influence energy expenditure and hepatic lipid and glucose metabolism. A fatty-acid side chain enables albumin binding and the weekly administration interval.
Semaglutid
Long-acting agonist at the GLP-1 receptor. Structurally a modified glucagon-like peptide 1 whose long half-life is achieved via a fatty-acid side chain and reversible albumin binding. Acts centrally on satiety and peripherally on glucose-dependent insulin secretion and delayed gastric emptying.
Evidence base
Highest evidence
Human RCT
Human RCT
Studies
4
4
of which in humans
4
3
Effects recorded
4
3
Open conflicts
0
1
Documented adverse events
0
5
Legal status
Full entries
Frequently asked questions
- What is the difference between Mazdutide and Semaglutid?
- Mazdutide is classified as "Metabolic", while Semaglutid is classified as "Metabolic". Mazdutide: Synthetic oxyntomodulin analogue that simultaneously activates the GLP-1 and glucagon receptors (dual agonist). Developed by Innovent Biologics and Eli Lilly. In China the NMPA approved mazdutide on 27 June 2025 for chronic weight management; a further filing for type 2 diabetes is under review in China. Outside China the substance remains in clinical development. Semaglutid: Long-acting GLP-1 receptor agonist. Approved as a medicinal product for type-2 diabetes (Ozempic, Rybelsus), chronic weight management (Wegovy) and cardiovascular risk in obesity. One of the best-studied substances on this platform — many large human RCTs. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Mazdutide or Semaglutid?
- The highest available evidence level is "Human RCT" for Mazdutide and "Human RCT" for Semaglutid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Mazdutide and Semaglutid in Germany and the United States?
- Germany: Mazdutide — Research only, Semaglutid — Prescription. United States: Mazdutide — Research only, Semaglutid — Prescription. These are factual summaries with source and review date on the individual pages.